Simeprevir with peginterferon [alpha]-2a/ribavirin for chronic hepatitis C virus genotype 1 infectio...
Simeprevir with peginterferon [alpha]-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study
About this item
Full title
Author / Creator
Gane, Edward J , DeJesus, Edwin , Janczewska, Ewa , George, Jacob , Diago, Moises , Da Silva, Mariliza Hendrique , Reesink, Henk , Nikitin, Igor , Hinrichsen, Holger , Bourgeois, Stefan , Ferenci, Peter , Shukla, Umesh , Kalmeijer, Ronald , Lenz, Oliver , Fevery, Bart , Corbett, Chris , Beumont, Maria and Jessner, Wolfgang
Publisher
BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
This Phase 3, open-label, rollover study (NCT01323244) investigated the efficacy and safety of simeprevir plus peginterferon [alpha]-2a (PegIFN[alpha]-2a) and ribavirin (RBV) in a well-characterized population of HCV genotype 1 (GT1)-infected treatment-experienced patients. Treatment comprised simeprevir 150 mg once daily (QD) plus PegIFN[alpha]-2a...
Alternative Titles
Full title
Simeprevir with peginterferon [alpha]-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_gale_infotracmisc_A507275063
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracmisc_A507275063
Other Identifiers
ISSN
1471-2334
E-ISSN
1471-2334
DOI
10.1186/s12879-017-2444-3
